ERBB2 and breast cancer: Additionally, several smaller-size immunoconjugates, such as affibodies (MW: 6–7 kDa) and single-domain antibody-fragments (VHH molecules; MW: 12–15 kDa), are currently being evaluated for imaging and targeted radiotherapy of HER2-positive breast cancers [10,15,16].